Company intelligence / Profile preview

Immix Biopharma

Los Angeles, California, United Statesimmixbio.com ↗

Ownership: Public · IMMX
Development stage: Other

Overview

Immix Biopharma’s lead asset, NXC‑201, a BCMA-targeted CAR-T cell therapy, has shown strong efficacy in relapsed/refractory AL amyloidosis with a reported overall response rate of 92% and complete response rates up to 71% in recent Phase 1b/2a studies. No neurotoxicity or major safety signals have been observed. The company has received FDA Orphan Drug Designation and RMAT designation for NXC‑201 in AL amyloidosis. Additional programs include IMX‑110 for solid tumors and soft tissue sarcoma currently in early clinical development.

Therapeutic areas: HematologyGastroenterologyOncology
Modalities: CAR-T cell therapySmall moleculeAntibody (for pipeline assets)
Industry: Biotech

Drug pipeline

4 assets

IMX-110

3 more assets in the full pipeline.

Financials

Market cap: $596.9M
Total revenue: $0
Enterprise value: $365.8M

Beyond the preview

Go deeper on Immix Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immix Biopharma.